COVID-19 vaccine effectiveness in adults aged 60 years and older: A case-control study in south India

Abstract

Objective: To evaluate the effectiveness of COVID-19 vaccines in preventing symptomatic and severe diseases among the adults aged 60 years and older, identify key risk factors that influence infection and severity, and explore strategies to enhance the protection for this high-risk group.
Methods: A test-negative case-control study was conducted among individuals aged 60 years and older, comprising 300 COVID-19-positive cases and 300 COVID-19-negative controls. Data on vaccination status and other variables were collected via telephone interviews using a pre-tested questionnaire. Vaccine effectiveness was calculated as 1 minus the crude odds ratio (OR), with 95% confidence interval (CI). Additionally, univariate logistic regression and multivariable logistic regression were employed to identify factors associated with SARS-CoV-2 infection and disease severity.
Results: Among 600 participants, 13.7% (82/600) were identified as unvaccinated individuals. Multivariable analysis revealed that vaccinated status was the only factor determining both the infection of SARS-CoV-2 (adjusted OR 2.63; 95% CI: 1.57-4.41) and severity of COVID-19 (adjusted OR 1.85; 95% CI: 1.00-3.62). The estimated vaccine effectiveness was 68.0% (95% CI: 0.45-0.82) for fully vaccinated individuals and 59.0% (95% CI: 0.30-0.76) for partially vaccinated individuals. Of the cases, 22.0% (66/300) were identified as severe. The vaccine demonstrated an effectiveness of 73.0% (95% CI: 0.47-0.86) against severe COVID-19 among fully vaccinated individuals and 68.0% (95% CI: 0.44-0.83) for partially vaccinated individuals.
Conclusions: The effectiveness of COVID-19 vaccines among the adults aged 60 years and older is lower than anticipated. In addition to the administration of booster doses, other interventions such as using higher doses, adjuvants, and intradermal routes should be evaluated to protect this highly vulnerable group that is at the greatest risk of adverse outcomes.

Keywords

COVID-19 vaccine / Vaccine effectiveness / Severity

Conflict of interest statement

The authors declare that there is no conflict of interest.

Acknowledgement

We place on record our gratitude to Dr. Rathan U. Kelkar, State Mission Director, National Rural Health Mission, Government of Kerala, India, for being a constant source of motivation and supporting the work at all stages. We would like to express our sincere gratitude to the Director of Health Services, Kerala V.R.Raju , Dr Preetha P.P, Additional Director Family Welfare, and Dr Sandeep K Deputy Director Family Welfare. We also place on record our gratitude to Dr. Ramla Beevi A., Director of Medical Education, Dr. Anuja U. and Dr. Indu P.S, heads of department of Community Medicine at Government Medical College, Thiruvananthapuram and Kollam, respectively for all the support for the conduct of the study. We would also like to acknowledge the contributions of Dr Rosin, Dr Mathew J. Valamparampil, Dr. Athira, Mr. Nithin.B.G, Mrs.Beula.G.S, Mrs. Akhila Kumari.V.S, Mrs. Remya.K.R from National Health Mission, State Program Management and Support Unit (NHM SPMSU).

Funding

This work was supported by National Health Mission, Kerala, India

Data availability statement

The data supporting the findings of this study are available from the corresponding author upon request.

Authors’ contributions

Thomas SB, Nujum ZT and Ramakrishnan D conceptualized and designed the study protocol. Paul L and Divya SN were instrumental in getting the data and resources, Nujum ZT did the analysis, Thomas SB was responsible for overall supervision, Nujum ZT and Thomas SB drafted the manuscript; Ramakrishnan D, Paul L and Divya SN critically revised the manuscript for intellectual content. All authors read and approved the final manuscript. Thomas SB and Nujum ZT are guarantors of the paper.

References

[1] World Health Organization. Evaluation of COVID-19 vaccine effectiveness: Interim guidance. [Online] Available from: https://apps.who.int/iris/handle/10665/340301. License: CC BY-NC-SA 3.0 IGO. [Accessed on 18 May 2024].

[2] National Health Mission. Guideline for COVID-19 vaccination for the priority groups. [Online] Available from: https://arogyakeralam.gov.in/wp-content/uploads/2021/02/Guideline-for-COVID19-Vaccination-for-the-priority-groups.pdf. [Accessed on 18 May 2024].

[3] World Health Organization. Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections hospitalisations associated with laboratory-confirmed SARS-CoV-2: An evaluation using the test-negative design. [Online] Available from: https://www.who.int/europe/publications/i/item/WHO-EURO-2021-2481-42237-58308. [Accessed on 18 May 2024].

[4] Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R. World Health Organization solidarity vaccines trial expert group. COVID-19 vaccine trials should seek worth-while efficacy. Lancet 2020; 396: 741-743.

[5] Teo SP. Review of COVID-19 vaccines and their evidence in older adults. Ann Geriatr Med Res 2021; 25(1): 4-9.

[6] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397(10269): 99-111.

[7] Veronese N, Petrovic M, Benetos A, Denkinger M, Gudmundsson A, Knol W, et al. Underrepresentation of older adults in clinical trials on COVID-19 vaccines: A systematic review. Ageing Res Rev 2021; 71: 101455.

[8] Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in older people. Age Ageing 2021; 50(2): 279-283.

[9] Gomes D, Beyerlein A, Katz K, Hoelscher G, Nennstiel U, Liebl B, et al. Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany. PloS ONE 2021; 16(11): e0259370.

[10] Grgič Vitek M, Klavs I, Učakar V, Serdt M, Mrzel M, Vrh M, et al. Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021. Euro Surveill 2022; 27(1): 2101110.

[11] Ng TW, Cowling BJ, Gao HZ, Thompson MG. Comparative immunogenicity of enhanced seasonal influenza vaccines in older adults: A systematic review and meta-analysis. J Infect Dis 2019; 219: 1525-1535.

[12] Baay M, Bollaerts K, Verstraeten T. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults. Vaccine 2018; 36: 4207-4214.

[13] Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2: Preliminary report. N Engl J Med 2020; 383: 1920-1931.

[14] Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and immunogenicity of SARSCoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-2438.

[15] World Health Organization. Smoking and COVID-19. [Online] Available from: https://www.who.int/news-room/commentaries/detail/smoking-and-covid-19. [Accessed on 21 May 2024].

[16] Sickbert-Bennett EE, Samet JM, Prince SE, Chen H, zeman KL, Tong HY, et al. Fitted filtration efficiency of double masking during the COVID-19 pandemic. JAMA Intern Med 2021; 181(8): 1126-1128.

[17] Huang YZ, Kuan CC. Vaccination to reduce severe COVID-19 and mortality in COVID-19 patients: A systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2022; 26(5): 1770-1776.

[18] Vo AD, La J, Wu JT, Stryimsh JM, Ronan M, Brophy M, et al. Factors associated with severe COVID-19 among vaccinated adults treated in US veterans affairs hospitals. JAMA Netw Open 2022; 5(10): e2240037.

[19] Satapathy P, Kumar P, Gupta JK, Rabaan AA, Al Kaabi NA, Mohanty D, et al. The emergence and implications of SARS-CoV-2 omicron subvariant BA.2.86 on global health. Int J Surg 2024; 110(4): 2498-2501.

[20] Lucero-Prisno III DE, Neyazi A, Ahmadi A, Tabesh O, Afzali H, Dzhusupov K, et al. Acceptability of COVID-19 vaccination in Herat, Afghanistan. [Online] Available from: https://rimj.org/pubs/index.php/journal/article/view/17. [Accessed on 17 November 2024].

[21] Shayan NA, Azizi AT, Razaqi N, Afzali H, Neyazi A, Waez H, et al. Phase wise assessment of COVID-19 related depression, anxiety, and stress level among patients in Herat city, Afghanistan-A descriptive study. [Online] Available from: https://rimj.org/pubs/index.php/journal/article/view/14. [Accessed on 17 November 2024].